|
Jean-François Formela is a Partner and joined Atlas Venture in 1993 to help build the US life sciences franchise.
Previously, he was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough in the US. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough's alpha-interferon. In his last position at Schering-Plough, he directed the US Phase IV studies in all therapeutic areas, as well as the health economics, medical information, and biotechnology pre-marketing groups. As a medical doctor, Jean-François practiced emergency medicine at Necker University Hospital in Paris.
Since joining Atlas Venture, Jean-François has been involved in the formation of companies such as Archemix, ArQule (NASDAQ: ARQL), Aureon Laboratories, Cellzome, deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM), Resolvyx Pharmaceuticals and SGX Pharmaceuticals (NASDAQ: SGXP). He was also an investor in Ciphergen Biosystems (NASDAQ: CIPH) and Nuvelo (NASDAQ: NUVO).
Jean-François currently serves on the Boards of Achillion Pharmaceuticals (NASDAQ: ACHN), Adnexus Therapeutics, ARCA Discovery, Proprius Pharmaceuticals, Resolvyx Pharmaceuticals and SGX Pharmaceuticals (NASDAQ: SGXP).
Jean-François received his MD from Paris University School of Medicine, and his MBA from Columbia University.
Investment Sector : Life Sciences
Boards :
Achillion, Adnexus Therapeutics, ARCA Discovery, Proprius Pharmaceuticals, Resolvyx Pharmaceuticals, SGX Pharmaceuticals
Featured Past Investments:
Archemix, ArQule, Ciphergen Biosystems, deCODE, Exelixis, MorphoSys, Nuvelo
In the News:
ARCA Discovery Completes $18 Million Equity Financing to Advance Targeted Cardiovascular Therapies and Submit Lead Product for Approval This Year
Achillion Announces the Promotion of Milind S. Deshpande, Ph.D. to Executive Vice President of Research
Achillion Announces the Resignation of John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer
SGX Pharmaceuticals to Present at the Sixth Annual JMP Securities Research Conference
Achillion to Present At the Sixth Annual JMP Securities Research Conference
Achillion Appoints OSI Executive Robert Van Nostrand to Board of Directors
Adnexus Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) on Clinical Product Candidate, CT-322 | 